MIRA
INFORM REPORT
|
Report Date : |
01.08.2007 |
IDENTIFICATION DETAILS
|
Name : |
MORVEL LABORATORIES PRIVATE LIMITED |
|
|
|
|
Registered Office : |
No.GL58,
Apollo Enlave, Highway, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2006 |
|
|
|
|
Date of Incorporation : |
16.05.1983 |
|
|
|
|
Com. Reg. No.: |
6187 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24231GJ1983PTC006187 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
AHMM03523C |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacturer, Trader and Exporter of Injectables Products. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 9000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well-established and reputed company having satisfactory
track. Directors are reported as experienced and respectable businessmen. Trade
relations are reported as fair. Business is active. Payments are usually
correct and as per commitments. The company can be considered normal for business dealings at usual
trade terms and conditions. |
LOCATIONS
|
Registered Office : |
No.GL58,
Apollo Enlave, Highway, |
|
Tel. No.: |
91-2762-645113 |
|
Mobile No.: |
91-9825025541 |
|
E-Mail : |
|
|
Website : |
|
|
Area : |
400 sq. ft. [Owned] |
|
|
|
|
Factory 1 : |
251 G.I.D.C. Estate, Near |
|
Tel. No.: |
91-2762-255041 / 255042 |
|
Fax No.: |
91-2762-240145 |
DIRECTORS
|
Name : |
Mr. Rikin Patel |
|
Designation : |
Managing Director |
|
Date of Birth/Age : |
22 Years |
|
Qualification : |
Engineering |
|
Experience : |
2 Years |
|
|
|
|
Name : |
Mrs. Meenaben K. Patel |
|
Designation : |
Director |
|
Date of Birth/Age : |
41 Years |
|
Qualification : |
B. Ed. |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer, Trader and Exporter of Injectables Products. |
|
|
|
|
Agencies Held : |
|
|
|
|
|
Exports : |
|
|
Countries : |
|
|
|
|
|
Terms : |
|
|
Selling : |
Cash and Credit [30-45 days] |
|
|
|
|
Purchasing : |
Cash and Credit [45-60 days] |
GENERAL INFORMATION
|
Customers : |
Wholesalers |
|
|
|
|
No. of Employees : |
70 [In Office : 10; In Factory : 40 and Marketing Staff : 20] |
|
|
|
|
Bankers : |
Bank of |
|
|
|
|
Facilities : |
Fixed Deposit to Quote Government tender |
|
|
|
|
Banking
Relations : |
Satisfactory |
|
|
|
|
Auditors : |
|
|
Name : |
Babubhai Patel and Company Chartered Accountants |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
150,000 |
Equity Shares |
Rs. 10/- each |
Rs. 1.500 Millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
130,000 |
Equity Shares |
Rs. 10/- each |
Rs. 1.300 Millions |
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
|
31.03.2006 |
31.03.2005 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
|
1.300 |
1.300 |
|
|
2] Share Application Money |
|
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
|
1.149 |
1.015 |
|
|
4] (Accumulated Losses) |
|
0.000 |
0.000 |
|
|
NETWORTH |
|
2.449 |
2.315 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
|
0.000 |
0.232 |
|
|
2] Unsecured Loans |
|
6.459 |
5.773 |
|
|
TOTAL BORROWING |
|
6.459 |
6.005 |
|
|
DEFERRED TAX LIABILITIES |
|
0.293 |
0.266 |
|
|
|
|
|
|
|
|
TOTAL |
|
9.201 |
8.586 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
|
5.958 |
2.600 |
|
|
Capital work-in-progress |
|
0.000 |
0.314 |
|
|
|
|
|
|
|
|
INVESTMENT |
|
1.144 |
1.144 |
|
|
DEFERREX TAX ASSETS |
|
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
|
6.020 |
6.358 |
|
|
Sundry Debtors |
|
5.833 |
3.552 |
|
|
Cash & Bank Balances |
|
1.327 |
1.485 |
|
|
Other Current Assets |
|
0.000 |
0.000 |
|
|
Loans & Advances |
|
0.487 |
0.504 |
|
Total
Current Assets |
|
13.667 |
11.899 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities |
|
11.523 |
7.361 |
|
|
Provisions |
|
0.045 |
0.010 |
|
Total
Current Liabilities |
|
11.568 |
7.371 |
|
|
Net Current Assets |
|
2.099 |
4.528 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
|
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
|
9.201 |
8.586 |
|
PROFIT & LOSS ACCOUNT
|
PARTICULARS |
|
31.03.2006 |
31.03.2005 |
|
|
Sales Turnover |
|
16.798 |
16.091 |
|
|
Other Income |
|
1.128 |
[0.439] |
|
|
Total Income |
|
17.926 |
15.652 |
|
|
|
|
|
|
|
|
Profit/(Loss) Before Tax |
|
0.128 |
0.197 |
|
|
Provision for Taxation |
|
0.075 |
0.063 |
|
|
Profit/(Loss) After Tax |
|
0.053 |
0.134 |
|
|
|
|
|
|
|
|
Expenditures : |
|
|
|
|
|
|
Manufacturing Expenses |
|
11.758 |
15.133 |
|
|
Purchases made for re-sale |
|
0.015 |
0.075 |
|
|
Employees Remuneration and Benefits |
|
1.175 |
0.737 |
|
|
Administrative Expenses |
|
0.460 |
0.495 |
|
|
Interest and Financial Expenses |
|
0.515 |
0.521 |
|
|
Selling and Distribution Expenses |
|
1.253 |
0.493 |
|
|
Loss on |
|
0.000 |
0.037 |
|
|
Depreciation & Amortization |
|
0.279 |
0.306 |
|
Total Expenditure |
|
15.455 |
17.797 |
|
KEY RATIOS
|
PARTICULARS |
|
|
31.03.2006 |
31.03.2005 |
|
PAT / Total Income |
(%) |
|
0.30 |
0.86 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
|
0.76 |
1.22 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
|
0.65 |
1.36 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
|
0.05 |
0.09 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
|
7.36 |
5.78 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
|
1.18 |
1.61 |
LOCAL AGENCY FURTHER INFORMATION
Trade Reference
- Sakshi Agencies,
Rajasthan [Jaipur]
- Bakshi
Medical Stores,
AS PER WEBSITE
Profile
Subject is a professionally managed pharmaceutical company
which was established in 1986. The company's strength is the manufacturing of a
wide range of quality medicines, specializing injectables both for human
(pharma) & Veterinary use. Morvel has its own pharmaceutical unit at
mehsana,
Subject
is now manufacturing a wide range of 35 injectables for human use and 34
injectables for veterinary use. Good manufacturing practice are strictly
adhered to during the production. The company possesses GMP [Good Manufacturing
process] with schedule M certificate and also has ISO 9002 certification. The
products conform to the global standards laid down under the Indian / British
and
Quality
Control i an important sea of excellence at morvel. All the raw materials and
packing materials are tested thoroughly and only those conforming to the
standard specifications are accepted. The advanced and latest technology in the
pharmaceutical manufacturing. Highly skilled, qualified and experienced staff
are employed in the manufacturing unit. With these high standards, subject
finds itself as one the leading pharmaceuticals with a wide range of products
in their country specially in the veterinary field.
Subject
has a wide distribution network through out the country. They believe in sound
ethical marketing. All their field executives are highly equipped with
the full knowledge of product information.
Subject is dedicated to the members of the
Medical & veterinary profession.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial Crime
:
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or investigation
registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.40.44 |
|
|
1 |
Rs.82.03 |
|
Euro |
1 |
Rs.55.42 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
6 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
5 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
6 |
|
--PROFITABILIRY |
1~10 |
4 |
|
--LIQUIDITY |
1~10 |
6 |
|
--LEVERAGE |
1~10 |
6 |
|
--RESERVES |
1~10 |
5 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
48 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|